Hippo/YAP pathway for targeted therapy.

Details

Serval ID
serval:BIB_343AE36E29C2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Hippo/YAP pathway for targeted therapy.
Journal
Translational Lung Cancer Research
Author(s)
Felley-Bosco E., Stahel R.
ISSN
2218-6751 (Print)
ISSN-L
2218-6751
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
3
Number
2
Pages
75-83
Language
english
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Abstract
Malignant pleural mesothelioma (MPM) is molecularly characterized by loss of function or mutations in the neurofibromin 2 (NF2) and the cyclin-dependent kinase inhibitor 2 genes. NF2 activates a cascade of kinases, called Hippo pathway, which downregulates Yes associated protein (YAP) function as transcription co-activator for TEA domain transcription factors (TEAD). In the absence of functional NF2, the expression of genes essential for cell cycling such as survivin is increased. New therapeutic strategies aimed at interfering with YAP activity include inhibition of hedgehog pathway, which downregulates the YAP protein, verteporfin, which inhibits the assembly of a functional YAP-TEAD transcription factor, and interference with thrombin and lysophosphatidic acid (LPA) receptors downstream signalling, since upon agonist binding they activate YAP.
Pubmed
Create date
12/08/2015 7:42
Last modification date
20/08/2019 13:20
Usage data